“Most of the major pharma companies are now engaging with QbD…many in the industry fail to understand how big a change in culture and practices it represents. It may be difficult at the onset for the initial development projects, but ultimately the pay-off will be great.” (Huw Kidwell, ‘Quality by Design – the new manufacturing paradigm’, 31/05/11)
We’re pleased to announce that Andreas Schneider, Vice President Life Science Alliances, Roche, will be speaking at the Early Drug Development Summit, 3rd – 4th December 2012 at the Hotel Palace Berlin, Germany.
He will be sharing his industry experience on maximising drug investments by effectively managing early drug development pipelines through the use of knowledge management. His presentation will address:
- Using data management and information to support knowledge management in early drug development
- Implementing QbD on individual steps of early development through to manufacturing
- Using knowledge in unit operations to aid quality risk assessment
- Utilising technical tools, software to gain knowledge out of data and identifying the gaps in knowledge management
Visit the website to view the full programme and speaker list.
The two day conference offers pre-arranged one-to-one meetings between +30 pharma industry solution providers and +120 drug development experts as well as real life case studies from leading drug development companies; Roche, GSK, AstraZeneca, UCB and more. Attendees will network with leading early drug developers to discuss maximising drug investments, toxicology, safety and biomarkers.
For more information, click here.
World Trade Group (WTG) is a leading global integrated media company. Operating within the sectors of HR, energy, pharmaceutical, food and beverage, manufacturing and supply chain, we organise and run some of the leading annual business events, bringing together senior executives from world class organisations.
Source: World Trade Group